Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity DOI Creative Commons
Sarah Sanchez, Nicole Palacio, Tanushree Dangi

et al.

Science Immunology, Journal Year: 2021, Volume and Issue: 6(66)

Published: Oct. 14, 2021

SARS-CoV-2 has caused a global pandemic that infected more than 250 million people worldwide. Although several vaccine candidates have received emergency use authorization, there is still limited knowledge on how dosing affects immune responses. We performed mechanistic studies in mice to understand the priming dose of an adenovirus-based long-term immunity SARS-CoV-2. first primed C57BL/6 with adenovirus serotype 5 encoding spike protein, similar used CanSino and Sputnik V vaccines. The prime was administered at either standard or 1000-fold lower dose, followed by boost 4 weeks later. Initially, low induced responses relative prime. However, elicited were qualitatively superior and, upon boosting, exhibited substantially potent recall functional capacity. also report effects simian immunodeficiency virus (SIV) vaccine. These findings show unexpected advantage fractionating doses, warranting reevaluation trial protocols for other pathogens.

Language: Английский

Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants DOI Creative Commons
Felix Wussow,

Mindy Kha,

Tae Hyun Kim

et al.

npj Vaccines, Journal Year: 2023, Volume and Issue: 8(1)

Published: March 16, 2023

Abstract Emerging SARS-CoV-2 Omicron subvariants continue to disrupt COVID-19 vaccine efficacy through multiple immune mechanisms including neutralizing antibody evasion. We developed COH04S1, a synthetic modified vaccinia Ankara vector that co-expresses Wuhan-Hu-1-based spike and nucleocapsid antigens. COH04S1 demonstrated against ancestral virus Beta Delta variants in animal models was safe immunogenic Phase 1 clinical trial. Here, we report of analogous BA.1- Beta-specific vaccines protect Syrian hamsters from subvariants. Despite eliciting strain-specific responses, all three weight loss, lower respiratory tract infection, lung pathology following challenge with BA.1 or BA.2.12.1. While the BA.1-specifc affords consistently improved compared homologous BA.1, confer similar protection heterologous These results demonstrate variant-specific derivatives cross-protective immunity

Language: Английский

Citations

17
Molecular characterization of SARS-CoV-2 nucleocapsid protein DOI Creative Commons
Yanping Huang,

Junkai Chen,

Siwei Chen

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2024, Volume and Issue: 14

Published: May 23, 2024

Corona Virus Disease 2019 (COVID-19) is a highly prevalent and potent infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until now, the world still endeavoring to develop new ways diagnose treat COVID-19. At present, clinical prevention treatment of COVID-19 mainly targets spike protein on surface SRAS-CoV-2. However, with continuous emergence SARS-CoV-2 Variants concern (VOC), targeting therapy shows high degree limitation. The Nucleocapsid Protein (N protein) conserved in virus evolution involved key process viral infection assembly. It most expressed structural after humans has immunogenicity. Therefore, N as factor replication basic research application great potential value. This article reviews progress structure biological function protein, diagnosis drug order promote researchers’ further understanding lay theoretical foundation for possible outbreak sudden diseases future.

Language: Английский

Citations

7
Unraveling the role of the nucleocapsid protein in SARS-CoV-2 pathogenesis: From viral life cycle to vaccine development DOI
Yousra A. El‐Maradny,

Moustafa A. Badawy,

Kareem I. Mohamed

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 279, P. 135201 - 135201

Published: Aug. 30, 2024

Language: Английский

Citations

7
T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID DOI Creative Commons
Lavanya Visvabharathy,

Barbara A. Hanson,

Zachary S. Orban

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2021, Volume and Issue: unknown

Published: Aug. 9, 2021

Many people experiencing long COVID syndrome, or post-acute sequelae of SARS-CoV-2 infection (PASC), suffer from debilitating neurologic symptoms (Neuro-PASC). However, whether virus-specific adaptive immunity is affected in Neuro-PASC patients remains poorly understood. We report that exhibit distinct immunological signatures composed elevated humoral and cellular responses toward Nucleocapsid protein at an average 6 months post-infection compared to healthy convalescents. also had enhanced production IL-6 diminished activation CD8 + T cells. Furthermore, the severity cognitive deficits quality life disturbances were associated with a reduced diversity effector molecule expression cells but IFN-γ C-terminal domain protein. Proteomics analysis showed plasma immunoregulatory proteins pro-inflammatory antiviral response convalescents, which correlated worse neurocognitive dysfunction. These data provide new insight into pathogenesis syndrome framework for rational design predictive biomarkers therapeutic interventions.Adaptive altered manifestations COVID.

Language: Английский

Citations

35
Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity DOI Creative Commons
Sarah Sanchez, Nicole Palacio, Tanushree Dangi

et al.

Science Immunology, Journal Year: 2021, Volume and Issue: 6(66)

Published: Oct. 14, 2021

SARS-CoV-2 has caused a global pandemic that infected more than 250 million people worldwide. Although several vaccine candidates have received emergency use authorization, there is still limited knowledge on how dosing affects immune responses. We performed mechanistic studies in mice to understand the priming dose of an adenovirus-based long-term immunity SARS-CoV-2. first primed C57BL/6 with adenovirus serotype 5 encoding spike protein, similar used CanSino and Sputnik V vaccines. The prime was administered at either standard or 1000-fold lower dose, followed by boost 4 weeks later. Initially, low induced responses relative prime. However, elicited were qualitatively superior and, upon boosting, exhibited substantially potent recall functional capacity. also report effects simian immunodeficiency virus (SIV) vaccine. These findings show unexpected advantage fractionating doses, warranting reevaluation trial protocols for other pathogens.

Language: Английский

Citations

35